期刊文献+

重型溃疡性结肠炎56例的临床特点与治疗 被引量:1

Study on clinical manifestations and treatment of severe ulcerative colitis,report of 56 cases
下载PDF
导出
摘要 目的探讨重型溃疡性结肠炎(UC)的临床特点以及治疗转归。方法回顾性分析重型UC患者56例的临床资料。记录其临床表现及诊疗经过,对柳氮磺胺吡啶/5-氨基水杨酸、皮质激素、免疫抑制剂等药物疗效进行评价,并对手术病例进行分析。结果重型UC患者占此期间住院UC患者的34.8%(56/161),其中19.6%(11/56)伴肠道外表现;87.5%(49/56)为全结肠型病变,初发型、慢性持续型及慢性复发型分别占33.9%(19/56)、32.1%(18/56)和33.9%(19/56);45例(80.4%)重型UC经药物治疗缓解,7例(12.5%)最终手术治疗。结论对于重型UC,除积极系统的药物治疗外,应及时评估药物疗效,掌握手术时机。 Objective To evaluate the clinical characteristics of severe ulcerative colitis(UC) and to find the factors influencing treatment and outcome.Methods The clinical data of fifty six inpatients with severe UC during 2006 to 2010 were retrospectively reviewed and analyzed.These clinical data including onset,symptoms,signs,laboratory findings,endoscopic features,radiological and pathological findings as well as its clinical treatment.Patients with surgical treatment were also included in this study.Results Fifty six(34.8%) of 161 inpatients were suffered from severe ulcerative colitis,and 87.5%(49/56) of them had pancolitis.Patients with first onset,chronic persistence and chronic recurrent type were accounted for 33.9%(19/56),32.1%(18/56) and 33.9%(19/56) respectively.Forty five cases(80.4%) could be relieved by drug therapy.Seven cases(12.5%) were progressed to take operation.Conclusion Most patients with severe UC respond well to medical treatment,but in some non-responding or corticosteroid depending individuals,surgical treatment should be considered after reasonable duration of medical treatment.
作者 陆霞娟
出处 《临床和实验医学杂志》 2012年第19期1525-1526,1528,共3页 Journal of Clinical and Experimental Medicine
关键词 溃疡性结肠炎 临床特点 治疗 转归 Ulcerative colitis Clinical characteristics Therapy Prognosis
  • 相关文献

参考文献8

二级参考文献39

  • 1王丹,郭晓林,朴云峰.巴柳氮治疗轻、中度溃疡性结肠炎24例[J].中国新药与临床杂志,2006,25(4):273-276. 被引量:6
  • 2欧阳钦,张虎.重症溃疡性结肠炎的诊断、评估与治疗[J].临床内科杂志,2006,23(8):512-514. 被引量:7
  • 3刘占举.巴柳氮钠治疗活动性溃疡性结肠炎的疗效观察[J].中华消化杂志,2007,27(5):295-298. 被引量:12
  • 4Baudet A, Rahmi G, Bretagne AL, et al. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother, 2008, 9 (3): 447-457.
  • 5Modigliani R. Medical management of fulminant colitis. Inflamm Bowel Dis, 2002, 8 (2): 129-134, 138-139.
  • 6Hanauer SB. Inflammatory bowel disease. N Engl J Med, 1996, 334 (13): 841-848.
  • 7Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut, 2004, 53 Suppl 5: V1-V16.
  • 8Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, 369 (9573): 1641-1657.
  • 9Wilhelm SM, McKenney KA, Rivait KN, et al. A review of infliximab use in ulcerative colitis. Clin Ther, 2008, 30 (2): 223-230.
  • 10Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther, 2005, 22 (10): 907-916.

共引文献788

同被引文献11

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部